Advanced Accelerator Applications: MHRA grants marketing authorisation for radioligand therapy Pluvicto (lutetium (177 Lu) vipivotide tetraxetan) in advanced prostate cancer in Great Britain. Novartis + Advanced Accelerator Applications.

Advanced Accelerator Applications (AAA), a Novartis company, announced that the Medicines & Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation in Great Britain for lutetium (177Lu) vipivotide tetraxetan, for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy or who are not medically suitable for taxanes.